Breast Cancer and Bones

Oestrogen/Estrogen is one of the main hormones protecting the bones. As we reach menopause - the Oestrogen/Estrogen production from the ovaries ceases. The cessation of Oestrogen/Estrogen starts to affect the metabolism of the bones with calcium and others. Over time the bones get weaker, leading onto osteopenia and then osteoporosis.

The main risk of osteoporosis of fractures of the bones.

Women (post-menopausal) with early stage breast cancer will benefit from bisphosphonate infusions (Zolendronate/Zometa) ranging from 6 monthly to 12 monthly for 3 years. There is a significant benefit in bone health, along with some improvement in breast cancer survival.

Women with metastatic breast cancer, involving the bones will benefit from Denosumab/Xgeva injections or Zometa infusions.

This is worth discussing with your Oncologist and General Practitioner.